Current therapeutic strategies for neurodegenerative disorders have predominantly focused on reducing pathological protein accumulation, particularly amyloid-β and tau in Alzheimer’s disease [11]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.